Pharming Group uproots angioedema gene therapy collab with Orchard Pharming currently markets the angioedema attack treatment Ruconest and the PI3Kδ syndrome med Joenja. The company ended ...

6 analysts have expressed a variety of opinions on Pharming PHAR over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of ...

Jefferies initiated coverage of Pharming (PHAR) with a Buy rating and $14 price target The firm believes the market is either underappreciating the Joenja opportunity treating rare disease ...

APDS is a genetic disorder that impairs the immune ... in adult and pediatric patients 12 years and older in March 2023. Pharming plans to include data from this 4-11-year-old trial in regulatory ...

Leiden, the Netherlands, December 11, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces positive ...

Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced a recommended public cash offer to ...

Leiden, the Netherlands, December 11, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces positive topline results of data from its Phase III ...